Higher PD-L1 expression of tumor cells have been showed to be associated with a better objective response to pembrolizumab, while good anti-tumor response to nivolumab occurred in patients regardless of PD-L1 expression (18, 19). This evidence concerns the gene CD274 and neoplasm.